Business Wire

Elliott Welcomes Bezeq’s Governance Overhaul

Jaa

Elliott Advisors (UK) Limited (“Elliott”), which advises funds that collectively comprise one of the largest shareholders in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), today sent a letter to Bezeq’s newly appointed Board Chairman Shlomo Rodav, sharing its views on Bezeq’s governance transformation and proposing that the Company consider a share buyback programme.

Elliott’s letter highlights the poor corporate governance that persisted at the Company over a number of years, leading to an Israel Securities Authority investigation, and a number of board members and executives being placed under house arrest and barred from the Company. Culminating in last week’s election of Chairman Rodav, the Company’s refreshed Board brings much needed independence and experience.

Now that the long overdue governance overhaul has been achieved, Elliott recommends that the following action items be undertaken without further delay: (i) appoint a new CEO; (ii) rebuild a constructive regulatory dialogue; (iii) develop a coherent new strategy for the business balancing growth with efficiency gains; (iv) review shareholder distribution policy, immediately seeking authorization to buy back shares and consider implementing a buyback programme when appropriate; and (v) conduct robust domestic and international engagement with shareholders, clearly communicating a plan to create value.

Elliott’s letter is latest in a series of communications with the Company this past year, and follows up on recent conversations with Chairman Rodav and other members of Bezeq’s board.

Full text of the letter can be read below.

About Elliott

Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.

***

May 17, 2018

 

Via Email

Mr Shlomo Rodav
Chairman
Bezeq The Israel Telecommunication Corporation Ltd.
The Triangular Tower
3 Azrieli Center
Tel Aviv 61620, Israel
Attention: Shlomo Rodav, Chairman of the Board of Directors
 

Dear Mr Rodav,

We appreciate our recent phone conversations about the future of Bezeq The Israel Telecommunication Corporation Ltd. (“Bezeq” or the “Company”). As the funds we advise are (collectively) one of Bezeq’s largest shareholders, we want to reiterate our optimism at your appointment as Chairman of the Board of Directors. Bezeq has undergone a major governance overhaul in recent months, providing a foundation for you and a new leadership team to drive shareholder value. We are writing today to offer our views on the importance of these governance changes and to propose that the Company consider supporting shareholder value by implementing a share buyback programme. Shares could be acquired from the market or, if feasible, from the Eurocom Group. To facilitate this, we believe Bezeq should immediately seek authorisation to acquire up to 10% of its shares, which would allow the Company to opportunistically buy back shares when appropriate.

Governance Transformation

Over the past year, Bezeq has operated under extreme uncertainty, with a lack of clear leadership and strategic direction, poor investor communications, and a stalled regulatory dialogue. These interrelated problems stemmed from the poor corporate governance that persisted at the Company over a number of years. This led to an Israel Securities Authority investigation and a number of board members and executives being placed under house arrest and barred from the Company. This has all occurred at a time of accelerating competition and change in the Israeli telecom market.

We are encouraged by the progress made in normalising Bezeq’s corporate governance. Following the AGM, and your subsequent election as Chairman, we believe that Bezeq now has a much improved Board of Directors. In contrast to when we first began our engagement with Bezeq, the Company’s refreshed Board is independent and brings experience of the Company itself and the Israeli telecom market as well as the management and governance of large companies. Having spoken with you and a number of your fellow directors, we are encouraged by your commitment to work collectively for the benefit of Bezeq and all its stakeholders without bias toward any shareholder who nominated you.

Valuation and Share Buyback

We continue to believe that Bezeq is fundamentally a well-positioned and resilient business, where—following a sustained period of poor governance and management—a new leadership team can drive performance improvements and rebuild shareholder value. Bezeq’s shares, in our view, are currently trading well below their fundamental value on multiple dimensions. Bezeq has one of the highest equity free cash flow yields (~11%) of any incumbent telecom company in the EMEA region. This yield is based on the 2018 earnings and cash flow, which we believe is likely to be a low point, reflecting the pricing initiative taken at Yes earlier this year, but none of the anticipated cost savings from combining Yes and Bezeq International. This also neglects the likely growth and efficiency initiatives that may be pursued by a new team. The shares trade well below the discounted cash flow valuations of every sell-side analyst covering the stock.

This discount to fundamentals implies that it would be accretive for Bezeq to buy back its own shares. This could be funded by the ~ILS 500m proceeds from the Sakia real estate disposal and by modest incremental borrowings, appropriately sized to avoid impacting Bezeq’s credit rating or significantly affecting borrowing costs.

Next Steps

Now that the governance problems at Bezeq have been resolved and a new Board of Directors is in place, it is imperative that the following steps be taken without further delay:

(i) Appoint a new CEO;

(ii) Rebuild a constructive regulatory dialogue;

(iii) Develop a coherent new strategy for the business balancing growth with efficiency gains;

(iv) Review shareholder distribution policy including immediately seeking authorization to buy back shares and consider implementing a buyback programme when appropriate; and

(v) Conduct robust domestic and international engagement with shareholders, clearly communicating a plan to create value.

Bezeq’s new Board should be well positioned to effectively govern the company in the interest of all shareholders. We appreciate your leadership in this new phase for Bezeq, and look forward to our continued dialogue.

Yours sincerely,

Elliott Advisors (UK) Limited

Contact information

Media
London
Sarah Rajani CFA
Elliott Advisors (UK) Limited
+44 (0) 20 3009 1475
srajani@elliottadvisors.co.uk
or
Tel Aviv
Eyal Arad
+972 (54) 669-9996
eyal@aradcomm.co.il

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial22.5.2018 20:19Tiedote

Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006139/en/ Zephyr Endobronchial Valves (Photo: Business Wire) “The LIBERATE Study definitively proves that Zephyr Valves offer clinically meaningful improvements in three important areas for patients – the ability to breathe better, be more active, and enjoy an improved quality of life,” said the study’s lead investigator, Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University. He continued, “All primary and secondary endpoints were met, with Zephyr Valve treatment showing significant improvement for patients across multiple measures of breathing a

Seoul Semiconductor Announces the Availability of a Series of AC LED Modules22.5.2018 19:03Tiedote

Seoul Semiconductor, a leading global innovator of LED products and technology, announces a comprehensive series of AC LED modules that use the company’s patented Acrich AC LED technology. The modules are offered in designs from 200 to 10,000 lumens in round, rectangular and linear formats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006054/en/ Seoul Semiconductor Announces the Availability of a Series of AC LED Modules (Photo: Business Wire) These AC modules integrate Seoul Semiconductor’s patented Acrich AC driver technology with the company’s advanced LEDs, enabling the design of compact light fixtures with superior lighting performance, making these modules ideal for a wide range of lighting applications. “Lighting designers who are looking to significantly reduce the size, weight, and volume of their luminaire designs can select one of our standard round, rectangular, or linear AC module designs to develop a co

Medicortex Finland Announces Agreement with Pro-Lab22.5.2018 16:58Tiedote

Medicortex Finland Oy announces that it has entered into an agreement with a Canadian company Pro-Lab Diagnostics Inc. Pro-Lab will be responsible for the regulatory process and registration of the ProbTBI™ brain injury detection kit in Canada and UK. Following a brain injury, the diagnostic test will detect in urine and saliva a unique brain injury biomarker which has been discovered and characterized by Medicortex. The agreement gives Pro-Lab exclusive rights for sales in the UK and Canada from which Medicortex will receive royalties. The agreement between the parties is confidential and no other details about the content of the agreement are disclosed. Pro-Lab will be responsible for the clinical validation of the kit prior to the commercial launch in the territories. In addition to the licensing agreement, the parties intend to initiate a development collaboration, the details of which are being discussed currently. “We are very proud that Pro-Lab Diagnostics has chosen to cooperat

ResMed Studies Show Remote Monitoring and Automated Resupply Improve Adherence to PAP Therapy22.5.2018 15:55Tiedote

Remote patient monitoring and resupply programs have been shown to improve patient adherence to positive airway pressure (PAP) therapy, according to two separate studies presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference. Remote monitoring boosts compliance In the first study, medXcloud, a ResMed-assembled group of healthcare key opinion leaders, examined de-identified data of more than 2.6 million U.S. PAP users from ResMed’s world-leading remote monitoring network, AirView. Using this big data approach, researchers observed excellent adherence among patients initiating PAP therapy: 75 percent achieved the CMS compliance threshold.* This rate compares very favorably with that of non-cloud-connected PAP therapy and other chronic medical therapies – both around 50 percent. Plus, the large sample suggests that the findings are generalizable and likely to reflect real-world clinical care. Resupply program boosts long-term compliance In a separate

Asuragen to Launch the AmplideX® PCR/CE DMPK Kit and Present Growing Genetic Testing Portfolio at 2018 European Society of Human Genetics (ESHG) Conference22.5.2018 15:00Tiedote

Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy to use products for complex testing in genetics and oncology, today announced the launch of the AmplideX® PCR/CE DMPK Kit* to simplify analysis of repeat expansions within the DMPK gene, which is implicated in myotonic dystrophy type I (DM1), also known as Steinert’s disease. DM1 is an inherited form of muscular dystrophy that affects the muscles as well as multiple other organ systems, and its severity is largely determined by the size of the CTG trinucleotide repeat expansion within the DMPK gene. These expansions commonly extend beyond a thousand CTG repeats and therefore have required the use of cumbersome Southern blot technology to estimate their size. “The AmplideX DMPK Kit represented a significant improvement over our existing process for analyzing large DMPK expansions,” said Doctor Sophie Rondeau, PharmD, PhD, and Professor Jean-Paul Bonnefont, MD, PhD, of the Necker-Enfants Malades Hospital in Par

Phil Brakewell Set to Lead WilsonHCG's Executive Search Efforts Across EMEA; Forbes Ranks WilsonHCG Among Best Executive Recruiting Firms22.5.2018 15:00Tiedote

WilsonHCG, global leader and premium provider of innovative talent solutions, further expands its Executive Search division with the appointment of Director Phil Brakewell. Phil, who brings more than 14 years of talent acquisition leadership experience and most recently served as Head of Executive Search for ResourceBank, will be responsible for leading WilsonHCG’s efforts in the EMEA region. Prior to joining ResourceBank, Phil held consultant and resourcing leadership positions at Hitchenor Wakeford and The Caudwell Group – where he was responsible for developing the business internationally and drove innovative search solutions on behalf of a diverse range of clients. “WilsonHCG’s reputation speaks for itself,” said Phil. “WilsonHCG tailors its key service offerings – including Executive Search – to suit individual client needs, and I am thrilled to be part of such a dedicated, innovative team. The new Director position, covering EMEA, demonstrates our commitment to both Executive Se

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme